William Blair Reiterates Outperform Rating on Abbvie (ABBV): "competitive across the amylin class"

William Blair analyst Matt Phipps reiterated an Outperform rating on Abbvie (NYSE: ABBV)

The analyst commented, "Before the market open on Monday, March 9, AbbVie announced positive top-line results from a Phase I, multiple-ascending-dose (MAD) study of ABBV-295, a subcutaneous, long-acting amylin analog for the potential treatment of obesity. Overall, while additional details around titration schedules, target dose levels, and slope of the weight loss will be key for determining the competitive profile of ABBV-295, we believe the week 12 weight loss of roughly 10% is competitive across the amylin class, and therefore is an encouraging initial update."

For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.

Shares of Abbvie closed at $230.11 yesterday.

You May Also Be Interested In

• A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
• argenx SE (ARGX) PT Raised to $1,088 at BofA Securities
• RBC Capital Reiterates Outperform Rating on Abbvie (ABBV)